Evidence map›Paper›PMID 34267354›Full record

ArticleBone marrow transplantation2021

Cord blood index predicts engraftment and early non-relapse mortality in adult patients with single-unit cord blood transplantation.

Gaku Kondo, Fumihiko Ishimaru, Takaaki Konuma, Satoshi Takahashi, Yoshiko Atsuta, Atsuko Ogawa, Mutsuko Minemoto, Koichi Kashiwase, Fumihiro Azuma, Miyuki Ito and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Gaku KondoJapanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan.
Fumihiko IshimaruJapanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan. f-ishimaru@ktks.bbc.jrc.or.jp.ORCID http://orcid.org/0000-0002-7668-6083
Takaaki KonumaThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-1496-376X
Satoshi TakahashiThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID http://orcid.org/0000-0003-4404-2870
Atsuko OgawaJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Mutsuko MinemotoJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Koichi KashiwaseJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Fumihiro AzumaJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Miyuki ItoJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Keiichi IsoyamaShowa University Fujigaoka Hospital, Kanagawa, Japan.
Takeshi KobayashiTokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Kazuteru OhashiTokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Fumiaki NakajimaJapanese Red Cross Central Blood Institute, Tokyo, Japan.ORCID http://orcid.org/0000-0003-0703-7087
Kiyoshi HirumaHiruma Clinic, Tokyo, Japan.
Shigeyoshi MakinoToranomon Hospital, Tokyo, Japan.
Hideo MugishimaKawagoe Preventive Medical Center Clinic, Saitama, Japan.
Noriko NambaJapanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan.
Hirokazu TsunoJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Tadashi NagaiJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Kazuo MuroiJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Kazunori NakajimaJapanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Japanese Red Cross Kanto-Koshinetsu Cord Blood Bank

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

How to select optimal cord blood (CB) remains an important clinical question. We developed and validated an index of CB engraftment, the cord blood index (CBI), which uses three weighted variables representing cell doses and HLA mismatches. We modeled the neutrophil engraftment time with competing events by random survival forests for competing risks as a function of the predictors: total nucleated cells, CD34, colony-forming units for granulocytes/macrophages, and the number of HLA mismatches at the antigen and allele levels. The CBI defined three groups that had different neutrophil engraftment rates at day 30 (High, 83.7% [95% CI, 79.2-88.1%]; Intermediate, 77.0% [95% CI, 73.7-80.2%]; Low, 68.4% [95% CI, 63.6-73.2%]), platelet engraftment rates at day 60 (High, 70.4% [95% CI, 64.9-75.9%]; Intermediate, 62.3% [95% CI, 58.5-66.0%]; Low, 49.3% [95% CI, 44.2-54.5%]), and non-relapse mortality at day 100 (High, 14.1% [95% CI, 9.9-18.3%]; Intermediate, 16.4% [95% CI, 13.5-19.3%]; Low, 21.3% [95% CI, 17.1-25.5%]). This novel approach is clinically beneficial and can be adopted immediately because it uses easily obtained pre-freeze data of CB.

Indexed as

Cord Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationAntigens, CD34Fetal BloodGraft SurvivalGranulocytesHumansAntigens, CD34

Identifiers

PMID34267354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.